RecruitingEarly Phase 1NCT07188012

Safety and Dystrophin Expression of SPOT-mRNA03 in Duchenne Muscular Dystrophy (DMD) Patients

Studying Duchenne muscular dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shanghai Siponuoyin Biotechnology Co Ltd
Principal Investigator
Wang Jiwen
Shanghai Children's Medical Center
Intervention
mRNA(genetic)
Enrollment
9 enrolled
Eligibility
2-6 years · MALE
Timeline
20252026

Study locations (1)

Collaborators

Shanghai Children's Medical Center

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07188012 on ClinicalTrials.gov

Other trials for Duchenne muscular dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Duchenne muscular dystrophy

← Back to all trials